Edarbi
(Azilsartan medoxomil)PreclinicalSmall molecule
TakedaAzilsartan medoxomil is used to treat high blood pressure. It helps relax blood vessels so blood can flow more easily, reducing the strain on your heart.[1] Edarbi is currently being investigated across 2 indications[3], with its most advanced program in Preclinical.[1]
Edarbi is one of 100 small molecule programs targeting Cardiovascular Disease. It is currently in Preclinical.
2
Indications
26
Total Trials
1
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Primacor
SanofiApproved
Geodon
PfizerApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Midamor
PPadagis LLC
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Cagrilintide
Novo NordiskPhase 3
Pelacarsen
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Hypertension12 trials
Show 9 more trials
Hypertension10 trials
Show 7 more trials
Diabetes Mellitus1 trial
ART1 trial
Kidney Disease1 trial
1 more indication
High Blood Pressure1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Azilsartan medoxomil. EMBL-EBI & Wellcome Sanger Institute.
- [4]